S100A4 and hepatocellular carcinoma: Using the top three as examples: RASA1 was shown to be involved in the development of some sarcomas [53,54], CDK signaling was found to be a potential therapeutic target in hepatocellular carcinoma [55], and S100A4 was shown to maintain cancer-initiating cells in head and neck cancers [56].